Abstract
Background
Atrophic acne scarring often accompanies acne vulgaris. The efficacy of topical retinoids for treatment of acne is well documented; however, evidence for use in atrophic acne scars is limited.
Methods
In this randomized, split-face, double-blind study, subjects (age: 17–34 years, N = 121) with moderate-to-severe facial acne, with acne scars present, were treated with either trifarotene 50 μg/g or vehicle once daily for 24 weeks. Efficacy was assessed by absolute and percent change from baseline in atrophic acne scar counts, Scar Global assessment (SGA), and IGA success rates as well as acne lesion counts.
Results
At week 24, a statistically significantly greater reduction in the mean absolute change from baseline in the total atrophic scar count was noted in the trifarotene- vs vehicle-treated area (− 5.9 vs − 2.7; p < 0.0001) with differences between sides noted as early as week 2 (− 1.5 vs − 0.7; p = 0.0072). The SGA success rate was higher in the trifarotene side at week 12 (14.9% vs 5.0%, P < 0.05) and improved through week 24 (31.3% vs 8.1%, P < 0.001). Similarly, at week 24, the IGA success rate was higher with trifarotene (63.6% vs 31.3%, P < 0.0001) along with reductions in total (70% vs 45%) and inflammatory (76% vs 48%) lesion counts. The incidence of treatment-emergent adverse events was 5.8% (trifarotene) and 2.5% (vehicle); most common (> 1%) was skin tightness (1.7% vs 0.8%), and all events were mild to moderate in severity.
Conclusions
Trifarotene was effective and well tolerated in treating moderate-to-severe facial acne and reducing atrophic acne scars, with reduction of total atrophic scar count as early as week 2.
Trial Registration
Clinicaltrials.gov NCT04856904.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Trifarotene is the most recent topical retinoid to receive regulatory approval for treatment of acne; it has a very low systemic absorption, making it well suited for treatment of large skin areas. Clinical trials of trifarotene included evaluations of both facial and truncal acne and showed efficacy in both areas. |
In patients at increased risk for atrophic acne scarring, trifarotene cream significantly reduces the development of scars as well as improves appearance of existing atrophic scars. |
Introduction
Acne vulgaris is a chronic inflammatory skin disease that affects approximately 85% of the population [1, 2]. Although it often affects adolescents, acne can occur at any age and can persist into adulthood [1, 2]. With a multifactorial pathophysiology that affects pilosebaceous units, acne is a polymorphic disease that frequently presents with several types of lesions simultaneously [3,4,5,6]. Primary acne lesions can be non-inflammatory or inflammatory; secondary lesions that arise from primary lesions include scars and post-inflammatory hyperpigmentation (PIH) [6,7,8]. Approximately half of all acne patients have scarring. While scars are more common in patients with severe acne, they can also accompany mild acne [9]. Both active acne and its sequelae can have significant damaging effects on patients’ quality of life [10]. Currently, a lack of efficacious medical treatments for atrophic acne scarring exists. In addition, a time delay after the onset of acne before patients receive adequate treatment likely translates to increased scarring.
Atrophic acne scarring is speculated to develop from ongoing inflammation in the pilosebaceous unit, since the vast majority of scars originate from papules and pustules and cysts (inflammatory lesions) [11, 12]. Inflammatory lesions that resolve slowly are more likely scar, again highlighting the role of ongoing inflammation [12, 13]. Atrophic acne scars are associated with loss of tissue and dermal matrix [11]. Although the pathogenesis of acne scarring is not completely understood, an intricate cell-mediated immune response is central to both active acne lesions and altered wound healing that leads to scarring [14, 15].
Management of atrophic acne scars is challenging, and many experts recommend early and effective treatment as a preventive strategy [11]. Topical retinoids are well established in active acne treatment, and increasing evidence indicates that these drugs may also improve acne scarring [11, 16,17,18]. Topical retinoids can stimulate dermal fibroblasts to increase procollagen production and can increase epidermal thickness [19, 20]. Trifarotene, the latest topical retinoid to receive FDA and EU approval, has a unique mechanism of action, binding to retinoic acid nuclear receptor gamma (RAR-γ) [21, 22]. Furthermore, a transcriptomic and gene expression analysis by Dreno et al. found that trifarotene uniquely affects genes involved in cellular migration, inflammation, and reorganization of the cellular matrix while downregulating pro-fibrotic macrophages [23]. To date, these effects on epidermal and immune components of acne pathophysiology have only been associated with trifarotene. This controlled clinical study evaluated the effect of trifarotene on facial acne and atrophic scars.
Methods
Study Design
This was a 24-week, double-blind, vehicle-controlled, split-face (randomized right face vs left face) study evaluating the efficacy and safety of once-daily trifarotene cream in patients with moderate to severe facial acne and atrophic acne scarring. The study followed good clinical practice and the Declaration of Helsinki, and was reviewed and approved by independent ethics committees or institutional review boards according to local/national requirements. All patients (aged 18 or older) or their guardians (for patients younger than 18 years) provided written informed consent which included permission to use data and photos for scientific publications purposes. A total of 20 sites in the USA, Canada, and France participated, and the study was sponsored by Galderma. Ethics approval was obtained for the study conduct. Approval for the US and Canada was provided by wcg IRB for protocol RD.06.SPR.202395 and IRB tracking number 20211170. Approval for France was provided by Comite de protection des personnes Sud Mediterranee, Hopital Sainte Margeurite, Marseille, France, Ref CPP 2144, Ref SI 21.04.16.78234, EudraCT 2020–006050-51.
Inclusion/Exclusion Criteria
To be eligible to participate, patients were male or female, aged 17 to 35 years inclusive, and had a diagnosis of facial acne defined as Investigator’s Global Assessment (IGA) score of 3 (moderate) or 4 (severe) with the same score on each side of the face and ≥ 20 inflammatory lesions (at least 10 on each side), no more than 2 nodules, and a minimum of 10 total atrophic scars (≥ 2 mm). Acne and atrophic scar distribution between sides of the face had to be approximately symmetrical. For 1 month prior to screening and during the study, women of childbearing potential had to agree to urine pregnancy tests and to be abstinent or to use effective and approved contraceptive methods. If the woman was using an oral contraceptive that was also approved for acne treatment, a stable dose for 6 months prior to the screening visit was required. Patients were excluded if they had acne conglobate, acne fulminans, secondary acne, nodulocystic acne, or acne requiring systemic treatment; also excluded were those with any facial acne cysts or ≥ 3 excoriated lesions, known active or chronic allergies, or intolerance to trifarotene.
Study Treatment
Patient eligibility was evaluated over a 28-day screening period. Qualified patients completed baseline assessments and were randomized (left or right side face) to apply trifarotene or vehicle over a 24-week period. Prior to study initiation, a randomization list was generated and transmitted to the packaging organization for study drug labeling and assigned trifarotene or vehicle to the right or left side of the face for each study drug kit. Patients applied study medication under site supervision at the baseline visit and videotaped application of study medication to each side of the face to ensure correct application. They were provided skincare products including a gentle skin cleanser, oil absorbing moisturizer with SPF 30, and moisturizing lotion (Cetaphil® products, Galderma, Dallas, TX). Patients were allowed to use equivalent skincare products at their preference, and trifarotene application frequency could be reduced for up to 2 weeks during the first 4 weeks of treatment if dryness or irritation occurred.
Assessments
Patients were evaluated for safety and efficacy at weeks 1, 2, 4, 8, 12, 16, 20, and 24. The primary endpoint was absolute change from baseline in total atrophic acne scar count per half face at week 24. Additional secondary assessments on each half-face included changes in 2–4 mm and > 4 mm and total atrophic scar counts from baseline to week 20, scar global assessment (SGA, 5-point scale with 0 = clear to 4 = severe) and SGA success (proportion of subjects who achieved a score of clear/almost clear and ≥ 2 grade improvement), percent change in acne lesions (total, inflammatory, non-inflammatory), investigator global assessment (IGA, 5-point scale with 0 = clear to 4 = severe), and IGA success rates (clear/almost clear and ≥ 2 grade improvement). Digital photography of the face was also performed.
Patient-reported outcomes included self-assessment of clinical acne-related scars (SCARS) questionnaire at baseline, week 12, and week 24. This questionnaire used a 10-cm visual analog scale for severity and a 5-point Likert-type scale for appearance of scars for each side of the face.
Safety was assessed by collection of adverse events and evaluation of local tolerability parameters (erythema, scaling, dryness, and stinging/burning, 0 = none to 3 = severe) at each visit.
Statistical Methods
A sample size of 118 patients was planned for randomization, and a blinded sample size re-estimation was performed after 40 patients completed/discontinued the study to account for unknown variability. A summary based on observed case was provided for all primary and secondary endpoints and patient-reported outcomes. For these summaries, no data were imputed. Atrophic acne scar counts (and absolute and percent changes from baseline), SGA, IGA, and lesion counts were summarized at each analysis visit using descriptive statistics by treatment side. Differences between the trifarotene and the vehicle sides were also summarized by descriptive statistics. The hypothesis test for the primary endpoint was evaluated at the two-sided significance level 0.05. Student’s t-test was used for paired samples, with point estimate of mean difference and related 95% confidence interval (CI). For analysis of change from baseline in total atrophic acne scar counts to Week 24, missing counts were imputed using multiple imputation (MI) under the missing at random (MAR) assumption. It was expected that the pattern of missing data would be monotonic, with slight deviations being corrected by the Markov Chain Monte Carlo (MCMC) method of the SAS MI procedure. Separate imputations by treatment group were carried out. Linear regression was employed to model the missing acne counts, with the following covariates included in the imputation model: non-missing total atrophic acne scar counts from earlier time points.
Results
Demographics and Disease Characteristics
A total of 121 patients participated, with a mean age of 22 years. Most (84.3%) were 18 years or older, female (72.7%), and white (80.2%), 30.6% had darker skin types (Fitzpatrick IV and V), and 21.5% self-identified as Hispanic. Patient demographics and disease characteristics are shown in Table 1. Baseline disease characteristics were similar, with acne scar severity being mostly mild or moderate according to SGA (> 80%) and all acne severity as assessed by IGA being moderate or severe.
Efficacy
Scar Results
As shown in Fig. 1, a significantly superior reduction in atrophic scar count occurred on trifarotene-treated sides of the face compared to vehicle-treated sides. At week 24, the mean absolute change from baseline was − 6.2 ± 5.6 on the trifarotene-treated area compared to − 2.8 ± 3.9 on the vehicle area (Δ − 3.2, P < 0.0001). This was primarily due to a greater amount of reduction in 2–4 mm atrophic acne scars. As shown, there was a difference between treated sides as early as week 2 (P = 0.001), which continued at week 4 (P = 0.007) and weeks 8 through 20 (P < 0.0001). The total scar counts were similar between groups at baseline (Table 1), but by week 24, the total scar count was 5.4 ± 5.6 for trifarotene-treated areas and 9.1 ± 8.6 for vehicle-treated areas (percent reductions of 55.2% and 29.9%, respectively).
At baseline, the mean Investigator SGA scores were the same in trifarotene- and vehicle-treated areas (2.6 for each, Table 1). By week 24, trifarotene-treated sides were rated 1.3 ± 0.7 compared to 1.9 ± 0.9 in the vehicle-treated sides. Trifarotene had superior SGA success rates at 53.5% compared to 32.3% in the vehicle sides (P < 0.001). Figures 2 and 3 show clinical photos at baseline and week 24 with appreciable differences between the trifarotene- and vehicle-treated sides.
Acne Results
As expected, all acne results were statistically significantly superior in trifarotene- vs vehicle-treated sides. Table 2 presents results of the active acne lesion assessments. Total lesion counts separated significantly between group as early as week 1 (P = 0.0097), and differences persisted through week 24 (P < 0.0001). Reductions in inflammatory lesion counts were significantly superior on trifarotene-treated sides compared to vehicle-treated as early as week 2 and persisted superior through week 24 (P < 0.0001). Separation in non-inflammatory lesion counts occurred by week 1 and lasted through week 24 (P < 0.0001). Superior IGA success rate in trifarotene-treated vs vehicle-treated sides (63.6% vs 31.3%, respectively) emerged by week 4.
Patient Preference/Satisfaction
At baseline, a similar number of atrophic acne scars was reported on each side of the face. At week 24, when asked how many indents/holes they saw on their face, 49% reported “very few” on the trifarotene-treated side, as did 37% for the vehicle-treated side. Similarly, the mean severity rating for scars was 4.9 at baseline and 1.9 at week 24 with trifarotene and 4.9 at baseline and 2.6 at week 24 with vehicle. The mean severity rating for active acne was reduced from a mean of 5.1 to 1.9 in the trifarotene side; for vehicle the change was from 5.2 at baseline to 2.7 at week 24.
Safety
Both trifarotene and its vehicle were well tolerated with treatment emergent adverse events (TEAEs) occurring in 5.8% of trifarotene-treated sides of the face and 2.5% of vehicle-treated sides. A summary of adverse events is shown in Table 3. The most common adverse events were local events, such as skin tightness, pruritus, erythema, and rash. Two adverse events of special interest from one patient (burning sensation and erythema) were reported on the trifarotene-treated side; the same patient discontinued the study drug because of adverse events on the trifarotene-treated side of the face. No serious adverse events occurred during the study.
The mean erythema, scaling, dryness, and burning/stinging scores peaked at week 2 and were slightly higher in the trifarotene-treated vs vehicle-tested half faces (5.8% vs 2.5%). Mean scores for tolerability parameters gradually decreased after week 2 through week 24, and the majority of scores (> 60%) were either mild or moderate.
Discussion
The study met its primary endpoint, with reductions in atrophic acne scar counts from baseline to week 24 being greater on trifarotene-treated facial sides compared to vehicle-treated sides. Secondary endpoints also showed that trifarotene was more effective than vehicle in reducing atrophic acne scarring. Trifarotene achieved superior results on all active acne assessments (lesion counts and IGA scoring) despite the small sample size and the study not being powered for acne lesions. Patients also reported better results on trifarotene vs vehicle sides in multiple aspects of their atrophic acne scars and active acne lesions. Trifarotene efficacy was observed as early as week 2 and increased over time until week 24. Furthermore, trifarotene showed a highly favorable risk-benefit ratio, with no new safety signals reported.
Topical retinoids, including trifarotene, inhibit inflammatory pathways that are activated in acne, including leukocyte migration, activation of Toll-like receptors, and the activator protein-1 pathway [15]. Trifarotene has strong and selective activity on RAR-γ and less pronounced effects on RAR-α and RAR-β; RAR-γ is the most prevalent RAR isoform in skin [22]. This selectivity may allow action on keratinocytes while reducing the potential for systemic adverse events [24]. Trifarotene regulates multiple skin functions, including epidermal keratinization, differentiation, maturation, and proliferation [24]; trifarotene downregulates matrix metalloproteinases and may improve skin texture by preserving elastin and collagen [22]. Recently, Dreno et al. found that trifarotene also affects gene expression and reduces profibrotic macrophages [23].
A reduction in atrophic acne scars was also shown with 6 months treatment with adapalene 0.3%/benzoyl peroxide 2.5% gel compared to vehicle [11]. Dreno et al. reported that the change from baseline in total scar counts increased on the vehicle-treated side but significantly decreased on the actively treated side (P < 0.0001) [11]. In addition, a significantly higher percentage of patients were considered to have success with adapalene/BPO on scar global assessment (32.9% vs 16.4% with vehicle, P < 0.01) [11].
Trifarotene has been shown to have excellent efficacy against acne lesions, and experts have long considered that effective treatment of acne inhibits scar formation [9, 25, 26]. With low systemic absorption, trifarotene may be used on large areas of the body, such as the trunk, in addition to the face [22, 25, 27]. According to the phase III studies of trifarotene, the improvements in active acne were similar on the face and the trunk; therefore, it is a reasonable assumption that trifarotene would then reduce truncal scarring [25]. It is not uncommon for truncal acne to cause persistent scarring, including macular atrophic scars and keloidal scars. While early and effective treatment can be used as a preventive strategy, more aggressive treatment should be offered to patients with existing scars. Truncal acne is often undertreated, and we recommend close examination of the trunk of patients with acne to assess current scarring and scarring risk. Currently, there is a lack of efficacious medical treatments for atrophic acne scarring. In addition, there is often a time delay after the onset of acne before patients receive adequate treatment, which likely translates to increased scarring. Scars have a negative impact on quality of life, both when on the face and on the trunk. A multidisciplinary research of truncal acne is needed to understand its pathogenic characteristics and proper management options.
Limitations of this study are the split-face design and potential of inadvertent contamination of trifarotene from one facial half to the other during the 24 weeks of treatment or from patients transferring cream by touching their face during the day. This was mitigated by using e-diaries during patient applications to ensure adherence and monitor correct application. However, consistent differences were observed between active and vehicle sides, with assessments showing continuous reductions in both active acne lesions and atrophic scars during the study.
Conclusions
Overall, trifarotene clearly reduced atrophic acne scars at week 24, with differences between sides noted as early as week 2. Additionally, trifarotene was well tolerated with a good safety profile.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Change history
12 January 2024
A Correction to this paper has been published: https://doi.org/10.1007/s13555-023-01090-z
References
Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172(Suppl 1):3–12.
Canavan TN, Chen E, Elewski BE. Optimizing non-antibiotic treatments for patients with acne: a review. Dermatol Ther (Heidelb). 2016;6:555–78.
Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60:S1-50.
Thiboutot DM, Dreno B, Abanmi A, et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78:S1-S23 e1.
Gollnick HP. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol. 2015;29(Suppl 5):1–7.
Abdel Hay R, Shalaby K, Zaher H, et al. Interventions for acne scars. Cochrane Database Syst Rev. 2016;4:CD011946.
Goodman GJ. Postacne scarring: a review of its pathophysiology and treatment. Dermatol Surg. 2000;26:857–71.
Layton AM, Seukeran D, Cunliffe WJ. Scarred for life? Dermatology. 1997;195(Suppl 1):15–21 (Discussion 38-40).
Tan J, Kang S, Leyden J. Prevalence and risk factors of acne scarring among patients consulting dermatologists in the Unites States. J Drugs Dermatol. 2017;16:97–102.
Chuah SY, Goh CL. The impact of post-acne scars on the quality of life among young adults in Singapore. J Cutan Aesthet Surg. 2015;8:153–8.
Dreno B, Bissonnette R, Gagne-Henley A, et al. Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: Results of a 6-month randomized, vehicle-controlled trial using intra-individual comparison. Am J Clin Dermatol. 2018;19:275–86.
Tan J, Bourdes V, Bissonnette R, et al. Prospective study of pathogenesis of atrophic acne scars and role of macular erythema. J Drugs Dermatol. 2017;16:566–72.
Bourdes V. Natural history of acne lesions and atrophic acne scars within a 6 month study period. Poster presented at 23rd World Congress of Dermatology, Vancouver, Canada. 2015.
Holland DB, Jeremy AH, Roberts SG, et al. Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar. Br J Dermatol. 2004;150:72–81.
Kang S, Cho S, Chung JH, et al. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol. 2005;166:1691–9.
Kang S, Leyden JJ, Lowe NJ, et al. Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks. Arch Dermatol. 2001;137:1597–604.
Dreno B, Bissonnette R, Gagne-Henley A, et al. Long-term effectiveness and safety of up to 48 weeks’ treatment with topical adapalene 0.3%/benzoyl peroxide 2.5% gel in the prevention and reduction of atrophic acne scars in moderate and severe facial acne. Am J Clin Dermatol. 2019;20:725–32.
Dreno B, Tan J, Rivier M, et al. Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split-face randomized controlled trial. J Eur Acad Dermatol Venereol. 2017;31:737–42.
Kang S, Fisher GJ, Voorhees JJ. Photoaging and topical tretinoin: therapy, pathogenesis, and prevention. Arch Dermatol. 1997;133:1280–4.
Kang S, Voorhees JJ. Photoaging therapy with topical tretinoin: an evidence-based analysis. J Am Acad Dermatol. 1998;39:S55-61.
Thoreau E, Arlabosse JM, Bouix-Peter C, et al. Structure-based design of Trifarotene (CD5789), a potent and selective RARgamma agonist for the treatment of acne. Bioorg Med Chem Lett. 2018;28:1736–41.
Aubert J, Piwnica D, Bertino B, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-gamma agonist trifarotene. Br J Dermatol. 2018;179:442–56.
Dreno B, Chavda R, Julia V, et al. Transcriptomics analysis indicates trifarotene reverses acne-related gene expression changes. Front Med. 2021;8: 745822.
Cosio T, Di Prete M, Gaziano R, et al. Trifarotene: a current review and perspectives in dermatology. Biomedicines. 2021;9:237.
Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 mug/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80:1691–9.
Tan J, Thiboutot D, Gollnick H, et al. Development of an atrophic acne scar risk assessment tool. J Eur Acad Dermatol Venereol. 2017;31(9):1547–54.
Blume-Peytavi U, Fowler J, Kemeny L, et al. Long-term safety and efficacy of trifarotene 50 mug/g cream, a first-in-class RAR-gamma selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2020;34:166–73.
Acknowledgements
The authors wish to thank the other START investigators: Melanie Appell, MD, Daniel Stewart, DO, Jonathan Weiss, MD, Jennifer Cather, MD, Jonette Keri, MD, Michael Bukhalo, MD, Paul Yamauchi, MD, Kenneth Steil, MD, Melinda Gooderham, MD, Joshua Berlin, MD, and Kyle Coleman, MD. The authors also wish to thank the study participants.
Medical Writing and Editorial assistance
Editorial assistance was provided by Valerie Sanders of Sanders Medical Writing.
Funding
Galderma funded the trial and Rapid Access Fees for this publication.
Author information
Authors and Affiliations
Contributions
Stephen Schleicher, Angela Moore, Elyse Rafal, Angelique Gagne-Henley, Sandra Marchese Johnson, Sunil Dhawan, JP York, Baldo Sforzolini, Kate Holcomb, Glynis Ablon, James Del Rosso and Brigitte Dreno: served as investigators in the study and approved in the final version of the manuscript were involved in study design and data analysis.
Corresponding author
Ethics declarations
Conflict of Interest
Dr. Schleicher has been a speaker for Almirall, Celgene, and Pfizer and has served as a Principal Investigator for Abbvie, Amgen, Astra Zeneca, Cara, Dr. Reddy, Encube, Eli Lilly, Exeltis, Foamix, Galderma, Genentech, Highlight, Nektar, NFlection, Novan, Regeneron, and Taro. Dr. Moore has received honoraria or research funds from Almirall, Galderma, Mayne, Ortho Dermatologics, Parexel, and Vyne. Dr. Rafal has served as an investigator for Abbvie, Actavis, Allergan, Amgen, Arcutis, Cassiopea, Celgene, Cutanea Life Sciences, Dermavant, Dermira, Dow, Dr. Reddy's Laboratories, Foamix, Galderma, MC2 Therapeutics, Novan, Pfizer, Sol–Gel Technologies, and Valeant. Dr. Gagné-Henley has received honoraria from AbbVie, Amgen, Bausch Health, Celgene, Galderma, Janssen, Novartis, Valeant, and Xenon. Dr. Johnson has been advisor or speaker for Nielsen, Amgen, Allergan, Regeneron, Sanofi Genzyme, and Candela, and an investigator for Arcutis, Aurigene, Amgen, Regeneron, Galderma, Nielsen, Dermavant, Lilly, Therapeutics, GSK, Aclaris, Foamix, Novartis, Abbvie, Gage, Cassiopea, National Psoriasis Foundation, and University of Pennsylvania. Dr. Dhawan S has served as an investigator for Galderma. Dr. Chavda, Dr. Sforzolini, and Dr. York are employees of Galderma. Dr. Holcomb has been a speaker or advisor for Galderma, Abbvie, Bristol Myers Squibb, Revanesse, Almirall, Evolus, Innocutis, and Ranbaxy and an investigator for Galderma, Abbvie, DermTech, Corevitas, Evols, Aclaris, and Neothetics. Dr. Ablon is an Investigator and speaker for Galderma, Bausch Health, Nutrafol, and Valeant. Dr. Del Rosso J has served as a consultant, investigator, and/or speaker for Ortho Dermatologics, Abbvie, Amgen, Arcutis, Dermavant, EPI Heath, Galderma, Incyte, LEO Pharma, Lilly, MC2 Therapeutics, Pfizer, Sun Pharma, and UCB. Pr Dreno has served as an investigator/consultant for Galderma, Pierre Fabre, La Roche Posay International, Novartis, Bristol-Myers Squibb, and Sun Pharma.
Ethical Approval
Ethics approval was obtained for the study conduct. Approval for the US and Canada was provided by wcg IRB for protocol RD.06.SPR.202395 and IRB tracking number 20211170. Approval for France was provided by Comite de protection des personnes Sud Mediterranee, Hopital Sainte Margeurite, Marseille, France Ref CPP 2144, Ref SI 21.04.16.78234, EudraCT 2020-006050-51. All patients and/or guardians provided written informed consent.
Additional information
The original online version of this article was revised: Missing row in Table 1 updated.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Schleicher, S., Moore, A., Rafal, E. et al. Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study. Dermatol Ther (Heidelb) 13, 3085–3096 (2023). https://doi.org/10.1007/s13555-023-01042-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13555-023-01042-7